INCREASED FREQUENCY OF EPSTEIN-BARR VIRUS EXCRETION IN PATIENTS WITH NEW DAILY PERSISTENT HEADACHES

doi:10.1016/S0140-6736(87)90119-X

The Lancet

Volume 329, Issue 8530, 21 February 1987, Pages 411-415

https://doi.org/10.1016/S0140-6736(87)90119-X Get rights and content

Abstract

In a case-control study 27 (84%) of 32 patients with new daily persistent headaches (NDPH) and 8 (25%) of 32 controls had evidence of Epstein-Barr virus (EBV) "active" infection, as demonstrated by EBV excretion and/or early antigen titre above 1:32. 20 (62%) patients and 4 (12%) controls were excreting EBV in the oropharynx, as determined by a dot hybridisation assay. The mean titre of IgG antibodies to early antigen was significantly higher in patients than controls. EBV reactivation may be important in the pathogenesis of NDPH. Alternatively, patients with NDPH may be unusually prone to EBV reactivation.

References (36)

R. Isaacs
Chronic infectious mononucleosis
Blood
(1948)
M. Tobi et al.
Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection
Lancet
(1982)
J. Meinkoth et al.
Hybridisation of nucleic acids immobilized on solid supports
Analyt Biochem
(1984)
Pwj Rigby et al.
Labelling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I
J Mol Biol
(1977)
W. Henle et al.
Epstein-Barr virus specific diagnostic tests in infectious mononucleosis
Hum Pathol
(1974)
Y. Ito et al.
Combined effect of the extracts from Croton riglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate and EBV expression in human lymphoblastoid P3HR-1 and Raji cells
Cancer Letl
(1981)
Rw Bartrop et al.
Depressed lymphocyte function after bereavement
Lancet
(1977)
Jb Jemmott et al.
Academic stress, power motivation, and decrease in secretion rate of salivary secretory immunoglobuun A
Lancet
(1983)
Dt Purtilo et al.
Documentation of Epstein-Barr virus infection in immunodeficient patients with life threatening lymphoproliferative diseases by clinical, virological and immunopathological studies
Cancer Res
(1981)
M. Ho et al.
Epstein-Barr virus infections and DNA hybridisation studies in post-transplantation lymphoma and lymphoproliferative lesions: The role of primary infection
J Infect Dis
(1985)

G. Miller

Epstein-barr virus

Rs Chong et al.

Recurrence of infectious mononucleosis

Lancet

(1980)

Jf Jones et al.

Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: Elevated anti-early antigen antibodies

Ann Intern Med

(1985)

Se Straus et al.

Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection

Ann Intern Med

(1985)

Lk Borysiewicz et al.

Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis

Quart J Med

(1986)

F. Diaz-Mitoma et al.

DNA-DNA dot hybridisation to detect Epstein-Barr virus in throat washings

J Infect Dis

(1987)

We Waters et al.

Epidemiology of headache and migraine in women

J Neurol Neurosurg Psychiat

(1971)

Cited by (100)

Current landscape of long COVID clinical trials
2024, International Immunopharmacology
Long COVID was reported as a multi-systemic condition after the infection of SARS-CoV-2, and more than 65 million people are suffering from this disease. It has been noted that around 10% of severe SARS-CoV-2 infected individuals are suffering from the enduring effects of long COVID. The symptoms of long COVID have also been noted in several mild or asymptomatic SARS-CoV-2 infected individuals. While limited reports on clinical trials investigating new therapeutics for long COVID exist, there is an abundance of scattered information available regarding these trials. This review explores the extensive literature search, and complete clinical trial database search to map the current status of long COVID clinical trials worldwide. The study listed about 110 long COVID clinical trials. In addition to conducting extensive long COVID clinical trials, we have comprehensively presented an overview of the condition, its symptoms, notable manifestations, associated clinical trials, the unique challenges it poses, and our recommendations for addressing long COVID.
Migraine and multiple sclerosis: The final answer?
2023, Multiple Sclerosis and Related Disorders
Systemic Factors in Temporomandibular Disorder Pain
2023, Dental Clinics of North America
Probable New Daily Persistent Headache After COVID-19 in Children and Adolescents
2022, Pediatric Neurology
Citation Excerpt :
The pathophysiology of NDPH remains unclear, although there are many widely recognized triggers. The link between infection and NDPH first became apparent when multiple patients with NDPH were found positive for Epstein-Barr virus.9 Rozen also noted that there have been many historical cases of new persistent headache after pandemics.10
Headache has been cited as both a primary symptom and a sequela of infection with the novel coronavirus. Cases of long coronavirus disease (COVID) headache have already been documented in adults, but literature on similar cases in children and adolescents is scant.
We present three cases of persistent headache after infection with COVID-19 in pediatric patients presenting to a tertiary headache center.
Infection has been suggested as a trigger for chronic headaches, specifically those of the new daily persistent headache type. Although the association between new daily persistent headache and COVID-19 remains unclear, these cases highlight the importance of awareness of the neurological sequelae of novel coronavirus infection in children and adolescents.
New daily persistent headache
2021, Pediatric Headache
New daily persistent headache (NDPH) is an often-refractory headache which presents with sudden onset. The day on which the patient develops the headache is distinct, and the time of onset is clearly remembered by the patient, with the pain becoming continuous and unremitting within 24 h.¹ Though a subset of children and adolescents with NDPH will respond quite nicely to treatment, unfortunately, many continue to experience daily headaches for years to come. Secondary etiologies must be excluded in patients in whom NDPH is suspected, as misdiagnosis can lead to inappropriate treatment and poor outcomes. Once a diagnosis is established the importance of early intervention cannot be overemphasized. These daily headaches can lead to missed school and extracurricular activities, as well as anxiety, depression, and significant strain upon the family. The onus is often on the primary care provider, who typically has first contact with the child with NDPH, to diagnose appropriately and treat aggressively, or to refer the patient to a headache specialist.
Influenza A virus: A possible trigger factor for hypnic headache?
2017, Neurologia

View all citing articles on Scopus

View full text

INCREASED FREQUENCY OF EPSTEIN-BARR VIRUS EXCRETION IN PATIENTS WITH NEW DAILY PERSISTENT HEADACHES

Abstract

Blood

Lancet

Analyt Biochem

J Mol Biol

Hum Pathol

Cancer Letl

Lancet

Lancet

Documentation of Epstein-Barr virus infection in immunodeficient patients with life threatening lymphoproliferative diseases by clinical, virological and immunopathological studies

Cancer Res

Epstein-Barr virus infections and DNA hybridisation studies in post-transplantation lymphoma and lymphoproliferative lesions: The role of primary infection

J Infect Dis

Epstein-barr virus

Recurrence of infectious mononucleosis

Lancet

Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: Elevated anti-early antigen antibodies

Ann Intern Med

Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection

Ann Intern Med

Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis

Quart J Med

DNA-DNA dot hybridisation to detect Epstein-Barr virus in throat washings

J Infect Dis

Epidemiology of headache and migraine in women

J Neurol Neurosurg Psychiat